Resumen del episodio
What would healthcare look like if genetics were built into drug discovery and disease prevention? In this Oxford+ in Brief episode, Susannah de Jager puts five quick-fire questions to Sir Peter Donnelly, CEO and co-founder of Genomics. Peter describes a future in which genetic evidence helps researchers develop medicines and select patients, while healthcare systems direct screening and prevention to the people who need them at the right time. He hopes this could lead to more effective medicines and longer, healthier lives. Peter also offers advice to founders entering Oxford: understand the demands, stay close to the mission and choose good colleagues. Susannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital. Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive Content…
What would healthcare look like if genetics were built into drug discovery and disease prevention? In this Oxford+ in Brief episode, Susannah de Jager puts five quick-fire questions to Sir Peter Donnelly, CEO and co-founder of Genomics. Peter describes a future in which genetic evidence helps researchers develop medicines and select patients, while healthcare systems direct screening and prevention to the people who need them at the right time. He hopes this could lead to more effective medicines and longer, healthier lives. Peter also offers advice to founders entering Oxford: understand the demands, stay close to the mission and choose good colleagues. Susannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital. Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive Content…
Episodios
Oxford+ In Brief with Peter Donnelly, CEO and Co-Founder of Genomics
EscuchadoWhat would healthcare look like if genetics were built into drug discovery and disease prevention? In this Oxford+ in Brief episode, Susannah de Jager puts five quick-fire questions to Sir Peter Donnelly, CEO and co-founder of Genomics. Peter describes a future in which genetic evidence helps researchers develop medicines and select patients, while healthcare systems direct screening and prevention to the people who need them at the right time. He hopes this could lead to more effective medicines and longer, healthier lives. Peter also offers advice to founders entering Oxford: understand the demands, stay close to the mission and choose good colleagues. Susannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital. Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive Content…
Human Genetics and AI with Sir Peter Donnelly
EscuchadoCould the same genetic data help us develop better medicines and identify disease risk years before symptoms appear? In this episode of Oxford+ in Partnership with Mishcon de Reya, Susannah de Jager speaks with Sir Peter Donnelly, CEO and co-founder of Genomics, about turning Oxford research into tools for drug discovery and preventative healthcare. Peter explains why assembling public data takes years of careful work, and how human genetics can help scientists choose drug targets and the patients most likely to benefit. The conversation also examines agentic AI, which lets scientists ask questions of genetic data without waiting for specialist analysis. On the healthcare side, Peter describes how polygenic risk scores could guide screening and prevention according to individual risk rather than age alone. Research reported by Exeter on 22 October 2026, drawing on nearly one million genomes, stresses that genetic risk needs clinical and environmental context. That distinction matters as Peter discusses…
Oxford+ In Brief with Gordon Sangera, Founder of Oxford Nanopore
EscuchadoWhat would success look like if Oxford turned more of its scientific discoveries into lasting businesses? In this Oxford+ in Brief episode, Susannah de Jager puts a series of quick-fire questions to Oxford Nanopore co-founder Gordon Sanghera. His answer starts with homegrown companies that remain independent and create jobs and wealth in the UK. He distinguishes independence from ownership, leaving room for overseas investors without abandoning that ambition. Gordon describes an Oxford innovation ecosystem with growing energy, pointing newcomers towards OX Tech Week and the Lamb & Flag. But he also argues that Oxford recognises promising technologies too slowly and should commit investment more quickly when a breakthrough appears credible. Looking towards 2050, Gordon imagines stronger late-stage development support in Oxford, drawing on the Fraunhofer model. His final proposal is more focused collaboration across fragmented research and spin-outs, organised around selected areas where Oxford could build…
How Gordon Sanghera Built Oxford Nanopore
EscuchadoWhat does it take to build a global deep tech company without leaving the UK? Oxford Nanopore co-founder Gordon Sanghera joins Susannah de Jager on Oxford+ in partnership with Mishcon de Reya to explain how an Oxford spinout became an international sequencing business. From his earlier work at MediSense to Nanopore’s London listing, Gordon describes the decisions that shaped the company and the gaps that still hold UK founders back. His account challenges cautious fundraising and the habit of proving a technology before planning its manufacture. He explains how honest budgets attracted patient capital, why building production capacity helped speed up development, and how employee share sales supported continuity through years of growth. The conversation comes as British Business Bank research published on 29 September reports UK venture funds matching US pooled total-value returns for 2002–2021 vintages. Fund performance and access to growth funding remain different questions, a distinction that runs through…
Oxford+ in Brief with Eva Barboni, Executive Director of Enterprise Britain
EscuchadoWhat would it take for Britain's best ideas to grow into global companies that stay here? In this Oxford+ in Brief episode, host Susannah de Jager puts a set of quick-fire questions to Eva Barboni, Executive Director of Enterprise Britain. Eva describes success as more scale-ups choosing to stay in Britain, creating jobs and reinvesting in their communities, with more Britons investing directly in the country's most exciting businesses. She argues that the UK is strong on innovation, with world-leading universities producing spin-outs in frontier technologies, but weak at backing those companies to commercialise and grow here. The gaps she identifies are capital to scale, a culture that champions success and access to talent. Eva Barboni: Eva Barboni is Executive Director of Enterprise Britain, where she campaigns for policies that help British companies grow and share the gains more widely. She has spent 20 years working across policy, communications and stakeholder engagement. Eva began her career on…